Document is current
Any future updates will be listed below
-
Authors
Boscenco, Sonia
Tait-Mulder, Jacqueline https://orcid.org/0000-0003-2834-8714
Kim, Minsoo
Tang, Cerise
Park, Tricia https://orcid.org/0000-0003-4471-004X
McNulty, Flora https://orcid.org/0000-0001-9555-0520
Lilla, Sergio https://orcid.org/0000-0003-3142-7640
Zanivan, Sara https://orcid.org/0000-0002-9880-9099
Huerta-Uribe, Alejandro
Nalbant, Benan
Zucker, Mark
Sumpton, David
Monteuuis, Geoffray
Jackson, Christopher B. https://orcid.org/0000-0003-1035-6417
Wei, Wei https://orcid.org/0000-0002-2945-3543
Chinnery, Patrick F. https://orcid.org/0000-0002-7065-6617
Chaligne, Ronan https://orcid.org/0000-0003-4332-3291
Lareau, Caleb A. https://orcid.org/0000-0003-4179-4807
Reznik, Ed https://orcid.org/0000-0002-6511-5947
Gammage, Payam A. https://orcid.org/0000-0003-1968-1726
-
Funding
Funding for this research was provided by:
Cancer Research UK (A31287 and A_BICR_1920_Gammage)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R37CA276200)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R37CA276200)
- License Information
-
More Information
Article History
Received: 8 November 2024
Accepted: 17 September 2025
First Online: 3 November 2025
Competing interests
: P.A.G. is a shareholder of Pretzel Therapeutics Inc. P.A.G. and E.R. are named inventors on a patent concerning the use of mtDNA mutations for cancer therapy stratification PCT/US2022/63/380,599. The other authors declare no competing interests.
